Journal
CURRENT PSYCHIATRY REPORTS
Volume 14, Issue 3, Pages 211-219Publisher
SPRINGER
DOI: 10.1007/s11920-012-0268-9
Keywords
Obsessive-compulsive disorder; OCD; Pharmacotherapy; Anxiety disorders; Algorithm; Treatment; Evidence-based; Primary care
Categories
Funding
- Abbott Laboratories
- AstraZeneca
- Eli Lilly and Company
- GlaxoSmithKline
- Jazz Pharmaceuticals
- Johnson Johnson
- H. Lundbeck A/S
- Orion Pharma
- Pfizer
- Pharmacia
- Roche
- Servier
- Solvay Pharmaceuticals
- Sumitomo
- Takeda
- Tikvah
- Wyeth
- Wellcome
- Cephalon
- ECNP
- Martin Dunitz Press
- Oxford University Press
- Janssen Pharmaceutica
- Bristol-Myers Squibb
- International College of OC Spectrum Disorders
- National Council for Scientific and Technological Development (CNPq)
- Rio de Janeiro State Research Support Foundation (FAPERJ)
- National Institute of Mental Health
- Neuropharm Ltd
- Transcept Pharmaceuticals
- Up to Date
- Cambridge University Press
- Grants-in-Aid for Scientific Research [22591294] Funding Source: KAKEN
Ask authors/readers for more resources
There is a need to synthesize the growing body of literature on the pharmacotherapeutic management of patients with obsessive-compulsive disorder for clinicians working at a primary care level. We have aimed to generate a simple, easy-to-follow algorithm for the primary care practitioner. This seven-step algorithm addresses diagnosis of obsessive-compulsive disorder, initiation of pharmacotherapy, monitoring and maintenance treatment, and guidelines for the management of patients who are resistant to initial therapy. In creating this algorithm, we have drawn on the body of published evidence, as well as on expert opinion.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available